T Lotti1,2,3. 1. Università degli Studi Guglielmo Marconi, Via Plinio, 44, 00193, Rome, Italien. professor@torellolotti.it. 2. Institute of Dermatology LifeCronos, Florence, Italien. professor@torellolotti.it. 3. World Health Academy Foundation, Zürich (CH), Schweiz. professor@torellolotti.it.
Abstract
BACKGROUND: Psoriasis is a chronic, inflammatory autoimmune skin disease that affects 1-3% of the world's population. Most patients with psoriasis have plaque psoriasis or psoriasis vulgaris, characterized by thickened erythematous scaly plaques and presenting in a variety of forms with distinct characteristics. Psoriasis is associated with a decreased quality of life as well as with severe comorbidities. OBJECTIVES: The aim of this spontaneous, retrospective observational clinical study was to evaluate the pharmacological activity of advanced treatment based on the use of UVA-1 laser therapy with or without the co-administration of low dose cytokines [interleukin (IL)-4, IL-10] and anti-IL-1 antibodies in patients affected by psoriasis vulgaris. RESULTS: In this study the efficacy of UVA-1 phototherapy and, in parallel, the decisive (statistically relevant) boosting activity of low-dose cytokines in ameliorating the Psoriasis Area Severity Index (PASI) score were assessed. These results show the effectiveness of combined use of phototherapy and low-dose cytokines therapy, highlighting the fundamental role of anti-inflammatory cytokines (IL-4, IL-10, anti-IL-1 antibodies) in the treatment of psoriasis vulgaris. CONCLUSION: Further studies are necessary to confirm these preliminary data.
BACKGROUND:Psoriasis is a chronic, inflammatory autoimmune skin disease that affects 1-3% of the world's population. Most patients with psoriasis have plaque psoriasis or psoriasis vulgaris, characterized by thickened erythematous scaly plaques and presenting in a variety of forms with distinct characteristics. Psoriasis is associated with a decreased quality of life as well as with severe comorbidities. OBJECTIVES: The aim of this spontaneous, retrospective observational clinical study was to evaluate the pharmacological activity of advanced treatment based on the use of UVA-1 laser therapy with or without the co-administration of low dose cytokines [interleukin (IL)-4, IL-10] and anti-IL-1 antibodies in patients affected by psoriasis vulgaris. RESULTS: In this study the efficacy of UVA-1 phototherapy and, in parallel, the decisive (statistically relevant) boosting activity of low-dose cytokines in ameliorating the Psoriasis Area Severity Index (PASI) score were assessed. These results show the effectiveness of combined use of phototherapy and low-dose cytokines therapy, highlighting the fundamental role of anti-inflammatory cytokines (IL-4, IL-10, anti-IL-1 antibodies) in the treatment of psoriasis vulgaris. CONCLUSION: Further studies are necessary to confirm these preliminary data.
Authors: M L Roberti; L Ricottini; A Capponi; E Sclauzero; P Vicenti; E Fiorentini; C Savoia; G Scornavacca; D Brazioli; L Gaio; R Giannetti; C Ignazzi; G Meloni; L M Chinni Journal: J Biol Regul Homeost Agents Date: 2014 Jan-Mar Impact factor: 1.711
Authors: T Lotti; J Hercogova; U Wollina; A A Chokoeva; Z Zarrab; S Gianfaldoni; M G Roccia; M Fioranelli; G Tchernev Journal: J Biol Regul Homeost Agents Date: 2015 Jan-Mar Impact factor: 1.711
Authors: A Chiricozzi; M Suárez-Fariñas; J Fuentes-Duculan; I Cueto; K Li; S Tian; C Brodmerkel; J G Krueger Journal: Br J Dermatol Date: 2015-11-11 Impact factor: 9.302